ELA
Envela Corporation
ELA offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
LCID
Lucid Group, Inc.
LCID has the edge over ELA overall, supported by stronger modeled upside and lower modeled downside.
ELA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Healthy | |
| Strong |
ELA's revenue, profitability, cash flow and balance sheet are all currently healthy.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ELA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $10.14 | -2.4% |
| Current | 12x | $10.39 | — |
| Fair | 18x | $15.50 | +49% |
| Forward | 19x | $10.39 | — |
| Expensive | 30x | $25.09 | +141% |
Historical ranges are pointers, not guarantees.
ELA's PE is in its cheap range at 12x. Analysts expect earnings to fall, which would put today's price at 19x next year's earnings, in its fair range.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
ELA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Decline | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect ELA's earnings and revenue to decline, with profitability weakening.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ELA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.56 | -35% |
| Q2 2026 | $0.85 | +150% |
| Q1 2026 | $0.80 | +176% |
| Q4 2025 | $0.56 | +115% |
| Q3 2025 | $0.41 | +64% |
| Q2 2025 | $0.34 | +36% |
| Q1 2025 | $0.29 | +16% |
| Q4 2024 | $0.26 | -3.7% |
| Q3 2024 | $0.25 | -42% |
ELA has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
ELA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $56.8M | +3.5% |
| Q1 2026 | $98.4M | +104% |
| Q4 2025 | $80.5M | +67% |
| Q3 2025 | $57.4M | +22% |
| Q2 2025 | $54.9M | +21% |
| Q1 2025 | $48.3M | +21% |
| Q4 2024 | $48.3M | +32% |
| Q3 2024 | $46.9M | +29% |
ELA's revenue has grown year over year for eight quarters in a row: $57M last quarter, up 3.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 9% | +3.1 points |
| Q1 2026 | 11% | +4.9 points |
| Q4 2025 | 9.4% | +5.4 points |
| Q3 2025 | 7.3% | +3 points |
| Q2 2025 | 5.9% | +1.7 points |
| Q1 2025 | 6.5% | +0.6 points |
| Q4 2024 | 3.9% | -0.4 points |
| Q3 2024 | 4.3% | -1.1 points |
ELA has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over ELA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
ELA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $5M | +137% |
| Q1 2026 | $20.6M | +2658% |
| Q4 2025 | -$3.7M | -215% |
| Q3 2025 | $2.2M | +51% |
| Q2 2025 | $2.1M | +$3.4M |
| Q1 2025 | $746.6K | -78% |
| Q4 2024 | $3.2M | +91% |
| Q3 2024 | $1.5M | +172% |
ELA has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
ELA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.8x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
| Q3 2024 | -0.4x | Net Cash |
ELA has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ELA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.8 | Oversold |
| Stochastic | 1.6 | Oversold |
ELA's weekly RSI is 30 (oversold) and its Stochastic is 2 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ELA PE vs Consumer Cyclical Sector
| Metric | ELA | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 32% below |
| PE % | 20 | 47 | 27 pts below |
ELA is trading at 12x earnings, a 32% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
ELA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 10% below |
| 20 week MA | $15.3 | 32% below |
| 50 week MA | $16.6 | 37% below |
| 100 week MA | $11.8 | 12% below |
| 200 week MA | $8.64 | 20% above |
ELA has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
ELA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.37 | $5.01 | +266% |
| 2021 | $5.01 | $4.10 | -18% |
| 2022 | $4.10 | $5.29 | +29% |
| 2023 | $5.29 | $4.86 | -8.1% |
| 2024 | $4.86 | $7.15 | +47% |
| 2025 | $7.15 | $12.5 | +75% |
| 2026 YTD | $12.5 | $10.4 | -17% |
ELA has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.